Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Elite Pharmaceuticals Inc. (ELTP : OTC)

• Company Description    Elite Pharmaceuticals, Inc. primarily engages in researching, developing, licensing, manufacturing, and marketing proprietary drug delivery systems and products. Their drug delivery technology involves releasing a drug into the bloodstream or delivering it to a target site in the body over an extended period of time or at predetermined times. Number of Employees: 68

• Price / Volume Information    Yesterday's Closing Price: $0.41 Daily Weekly Monthly 20 Day Moving Average: 801,225 shares Shares Outstanding: 1,077.00 (millions) Market Capitalization: $438.34 (millions) Beta: 0.33 52 Week High: $0.82 52 Week Low: $0.27 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -13.39% -13.46% 12 Week -22.80% -23.57% Year To Date -16.99% -17.42%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 165 LUDLOW AVENUE - NORTHVALE,NJ 07647 USA ph: 201-750-2646 fax: 201-750-2755 dianne@elitepharma.com http://www.elitepharma.com

• General Corporate Information    Officers Nasrat Hakim - Chief Executive Officer Carter Ward - Chief Financial Officer Barry Dash - Director Jeffrey Whitnell - Director Davis Caskey - Director Peer Information Elite Pharmaceuticals Inc. (GSAC) Elite Pharmaceuticals Inc. (CASI) Elite Pharmaceuticals Inc. (ALCD.) Elite Pharmaceuticals Inc. (OMNN) Elite Pharmaceuticals Inc. (CGPI.) Elite Pharmaceuticals Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 28659T200 SIC: 2834 Fiscal Year Fiscal Year End: March Last Reported Quarter: 12/01/25 Next Expected EPS Date: 06/29/26 Share - Related Items Shares Outstanding: 1,077.00 Most Recent Split Date: (:1) Beta: 0.33 Market Capitalization: $438.34 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 06/29/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: 40.70 PEG Ratio: - Price Ratios Price/Book: 5.46 Price/Cash Flow: 23.73 Price / Sales: 3.13 EPS Growth vs. Year Ago Period: 200.00% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: 119.92% vs. Previous Quarter: -13.03% ROE 12/31/25 - 47.93 09/30/25 - -0.72 06/30/25 - -9.88 ROA 12/31/25 - 25.81 09/30/25 - -0.35 06/30/25 - -4.72 Current Ratio 12/31/25 - 7.34 09/30/25 - 8.04 06/30/25 - 7.23 Quick Ratio 12/31/25 - - 09/30/25 - 6.34 06/30/25 - 5.44 Operating Margin 12/31/25 - 20.79 09/30/25 - -0.29 06/30/25 - -4.33 Net Margin 12/31/25 - 30.98 09/30/25 - 11.33 06/30/25 - -10.26 Pre-Tax Margin 12/31/25 - 39.42 09/30/25 - 19.32 06/30/25 - -1.39 Book Value 12/31/25 - 0.07 09/30/25 - 0.06 06/30/25 - 0.04 Inventory Turnover 12/31/25 - 3.48 09/30/25 - 3.15 06/30/25 - 2.67 Debt-to-Equity 12/31/25 - 0.05 09/30/25 - 0.06 06/30/25 - 0.09 Debt-to-Capital 12/31/25 - 4.50 09/30/25 - 5.97 06/30/25 - 8.03

Powered by Zacks Investment Research ©